Please login to the form below

Not currently logged in
Email:
Password:

Opsumit

This page shows the latest Opsumit news and features for those working in and with pharma, biotech and healthcare.

FDA ‘names and shames’ generic-blocking pharma companies

FDA ‘names and shames’ generic-blocking pharma companies

Pomalyst, followed by Actelion with 26 inquiries mainly for pulmonary artery hypertension drugs Tracleer and Opsumit.

Latest news

More from news
Approximately 8 fully matching, plus 10 partially matching documents found.

Latest appointments

  • J&J's Jane Griffiths named global head of Actelion J&J's Jane Griffiths named global head of Actelion

    At that point it will gain marketed products that include a trio of pulmonary artery hypertension (PAH) drugs - Tracleer (bosentan), Opsumit (macitentan) and Uptravi (selexipag). ... He also led and managed the highly successful launches of Opsumit,

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics